Pharmacological issues in the treatment of tuberculosis

被引：25

作者：

Peloquin, CA

机构：

[1] Natl Jewish Med & Res Ctr, Dept Med, Pharmacokinet Lab, Denver, CO 80206 USA

[2] Univ Colorado, Sch Pharm, Denver, CO 80206 USA

[3] Univ Colorado, Sch Med, Denver, CO 80206 USA

来源：

NEW VISTAS IN THERAPEUTICS, FROM DRUG DESIGN TO GENE THERAPY: DRUG-RESISTANT TUBERCULOSIS, FROM MOLECULES TO MACRO-ECONOMICS | 2001年 / 953卷

关键词：

pharmacology; tuberculosis; dosing regimen; cycloserine; toxicity; therapeutic drug monitoring;

D O I：

10.1111/j.1749-6632.2001.tb11374.x

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

A thorough review of the clinical trial data combined with new in vitro experimental information may make the optimization of dosages of TB drugs possible. Several factors can affect the selection and dosage of TB drugs including hepatic and renal impairment, pregnancy, duration of disease before treatment, and extent of debilitation. Drug interactions and pharmacodynamics must be considered, and their roles are discussed.

引用

页码：157 / 164

页数：8

共 27 条

[1]

[Anonymous], DRUG SUSCEPTIBILITY

[2] Once daily aminoglycoside therapy - Is it less toxic than multiple daily doses and how should it be monitored? [J].